Mon panier

Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein (Monomer, MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
HLH-H82E8-25ug
$125.00
HLH-H82E8-200ug
$700.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    HLA-A*0201 & B2M & HIV Gag (SLYNTVATL)

  • Source

    Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein (HLH-H82E8) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & SLYNTVATL peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769 (B2M) & SLYNTVATL).

    Predicted N-terminus: Gly 25 & Ser

    Request for sequence
  • Molecular Characterization

    Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein is produced by co-expression of HLA and B2M loaded with HIV Gag peptide.

    This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 36.3 kDa and 13.7 kDa. The protein migrates as 40-43 kDa and 14 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    HLA-A*0201 & B2M & HIV Gag (SLYNTVATL) SDS-PAGE

    Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    HLA-A*0201 & B2M & HIV Gag (SLYNTVATL) SEC-MALS

    The purity of Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein (Cat. No. HLH-H82E8) is more than 95% and the molecular weight of this protein is around 48-58 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     HLA-A*0201 & B2M & HIV Gag (SLYNTVATL) ELISA

    Immobilized Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein (Cat. No. HLH-H82E8) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-HLA class I Antibody, Human IgG1 (W6/32) with a linear range of 0.1-2 ng/mL (QC tested).

    Protocol
  •  HLA-A*0201 & B2M & HIV Gag (SLYNTVATL) ELISA

    Immobilized Biotinylated Human HLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein (Cat. No. HLH-H82E8) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Anti-B2M Antibody, Human IgG1 with a linear range of 0.1-2 ng/mL (Routinely tested).

    Protocol
  • Bioactivity-SPR

     HLA-A*0201 & B2M & HIV Gag (SLYNTVATL) SPR

    HIV Gag TCR captured on Protein A Chip can bind Biotinylated HumanHLA-A*02:01&B2M&HIV Gag (SLYNTVATL) Complex Protein (Cat. No. HLH-H82E8) with an affinity constant of 0.345 nM as determined in SPR assay (Biacore 8K) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

HIV (human immunodeficiency virus) is a virus that attacks the body’s immune system. If HIV is not treated, it can lead to AIDS (acquired immunodeficiency syndrome). It can be transmitted via the exchange of a variety of body fluids from infected people, such as blood, breast milk, semen and vaginal secretions, And from a mother to her child during pregnancy and delivery. This disease can be managed by treatment regimens composed of a combination of antiretroviral (ARV) drugs. The Human HLA-A*0201 HIV (SLYNTVATL) complex protein is a complex of HLA-A*0201 of the MHC Class I, B2M, and SLYNTVATL peptide of the HIV.

Progrès de frontière

 
Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte